Press Release
Ocular Therapeutix™ Appoints Daniel Bollag, Ph.D., as Senior Vice President, Regulatory Affairs, Pharmacovigilance and Quality
“We are excited a professional of Dan’s caliber will be joining us at
Ocular,” said
Dr. Bollag brings over 25 years of R&D and executive regulatory
leadership experience to
Eric Ankerud, Executive Vice President, Regulatory, Quality and
Compliance, will transition out of his current role and remain with the
Company as a Senior Advisor and consultant as he devotes additional time
to building his business consulting practice. Mr. Ankerud will continue
to provide
“We would like to thank Eric for his many contributions to
About Ocular Therapeutix, Inc.
Forward Looking Statements
Any statements in this press
release about future expectations, plans and prospects for the Company
including the development and regulatory status of the Company’s product
candidates, such as the Company’s expectations and plans regarding
product development efforts and regulatory submissions for and the
timing and conduct of clinical trials of DEXTENZA for the treatment of
post-surgical ocular inflammation and pain and OTX-TP for the treatment
of glaucoma and ocular hypertension, the ongoing development of the
Company’s sustained release intravitreal depot technology, the potential
utility of any of the Company’s product candidates, potential
commercialization of the Company’s product candidates, and other
statements containing the words "anticipate," "believe," "estimate,"
"expect," "intend", "goal," "may", "might," "plan," "predict,"
"project," "target," "potential," "will," "would," "could," "should,"
"continue," and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors. Such forward-looking statements involve substantial
risks and uncertainties that could cause the Company’s clinical
development programs, future results, performance or achievements to
differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among
others, those related to the timing and costs involved in
commercializing ReSure® Sealant or any product candidate that receives
regulatory approval, the initiation and conduct of clinical trials,
availability of data from clinical trials and expectations for
regulatory submissions and approvals, the Company’s manufacturing
operations, the Company’s scientific approach and general development
progress, the availability or commercial potential of the Company’s
product candidates, the availability of cash resources and need for
additional financing or other actions and other factors discussed in the
“Risk Factors” section contained in the Company’s quarterly and annual
reports on file with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20170803006333/en/
Source:
Investors
Burns McClellan
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Ocular
Therapeutix
George Migausky
Interim Chief Financial Officer
gmigausky@ocutx.com
or
Media
Ocular
Therapeutix
Scott Corning
Vice President of Marketing &
Commercial Operations
scorning@ocutx.com